Sutro Biopharma, Inc.
STRO
$20.48
-$0.83-3.90%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -32.25% | 24.69% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -32.25% | 24.69% | |||
| Cost of Revenue | -13.29% | -0.24% | |||
| Gross Profit | 0.79% | 11.86% | |||
| SG&A Expenses | 3.26% | -12.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.45% | -2.58% | |||
| Operating Income | -0.25% | 12.01% | |||
| Income Before Tax | -0.09% | 17.81% | |||
| Income Tax Expenses | 106.67% | 81.71% | |||
| Earnings from Continuing Operations | -0.13% | 17.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.13% | 17.70% | |||
| EBIT | -0.25% | 12.01% | |||
| EBITDA | -0.31% | 11.54% | |||
| EPS Basic | 20.96% | 45.06% | |||
| Normalized Basic EPS | 21.31% | 39.52% | |||
| EPS Diluted | 20.96% | 45.06% | |||
| Normalized Diluted EPS | 21.31% | 39.52% | |||
| Average Basic Shares Outstanding | 26.67% | 49.79% | |||
| Average Diluted Shares Outstanding | 26.67% | 49.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||